Critical role of alpha-toxin and protective effects of its neutralization by a human antibody in acute bacterial skin and skin structure infections

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 10, 2016, Pages 5640-5648

  Le, Vien T M ^a   Tkaczyk, Christine ^b   Chau, Sally ^a   Rao, Renee L ^a   Dip, Etyene Castro ^a   Pereira Franchi, Eliane P ^a   Cheng, Lily ^b   Lee, Sally ^b   Koelkebeck, Holly ^b   Hilliard, Jamese J ^b   Yu, Xiang Qing ^c   Datta, Vivekananda ^d   Nguyen, Vien ^e   Weiss, William ^e   Prokai, Laszlo ^e   O'Day, Terrence ^c   Stover, C Kendall ^b   Sellman, Bret R ^b   Diep, Binh An ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Department of Infectious Diseases ^*  (United States)

^c MEDIMMUNE   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e UNIVERSITY OF NORTH TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOXIN; HUMAN MONOCLONAL ANTIBODY; LINEZOLID; MEDI 4893; UNCLASSIFIED DRUG; BACTERIAL TOXIN; HEMOLYSIN; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; STAPHYLOCOCCAL ALPHA-TOXIN; SUVRATOXUMAB;

ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTION; ACUTE DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL LOAD; BACTERIAL SKIN DISEASE; BACTERIAL SURVIVAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE INCREASE; HUMAN; IMMUNOPROPHYLAXIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RABBIT MODEL; SKIN INFECTION; ANIMAL; BLOOD; DISEASE MODEL; GENETICS; IMMUNOLOGY; MICROBIOLOGY; PATHOGENICITY; PRE-EXPOSURE PROPHYLAXIS; PROCEDURES; RABBITS AND HARES; STAPHYLOCOCCAL SKIN INFECTIONS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; BACTERIAL TOXINS; DISEASE MODELS, ANIMAL; HEMOLYSIN PROTEINS; HUMANS; LINEZOLID; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; PRE-EXPOSURE PROPHYLAXIS; RABBITS; SKIN DISEASES, BACTERIAL; STAPHYLOCOCCAL SKIN INFECTIONS;

EID: 84992343795     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00710-16     Document Type: Article

References (37)

1. Moran GJ, Krishnadasan A, Gorwitz RJ, Fosheim GE, McDougal LK, Carey RB, Talan DA. 2006. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 355:666-674. http://dx.doi.org/10.1056/NEJMoa055356.
2. King MD, Humphrey BJ, Wang YF, Kourbatova EV, Ray SM, Blumberg HM. 2006. Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections. Ann Intern Med 144:309-317. http://dx.doi.org/10.7326/0003-4819-144-5-200603070-00005.
3. Diep BA, Chambers HF, Graber CJ, Szumowski JD, Miller LG, Han LL, Chen JH, Lin F, Lin J, Phan TH, Carleton HA, McDougal LK, Tenover FC, Cohen DE, Mayer KH, Sensabaugh GF, Perdreau-Remington F. 2008. Emergence of multidrug-resistant, community-associated, methicillin-resistant Staphylococcus aureus clone USA300 in men who have sex with men. Ann Intern Med 148:249-257. http://dx.doi.org/10.7326/0003-4819-148-4-200802190-00204.
4. U.S. Food and Drug Administration. Guidance for industry: acute bacterial skin and skin structure infections-developing antimicrobial drugs for treatment. U.S. Food and Drug Administration, Rockville, MD. http://www.fda.gov/downloads/Drugs//Guidances/ucm071185.pdf.Accessed 31 July 2015.
5. Rajendran PM, Young D, Maurer T, Chambers H, Perdreau-Remington F, Ro P, Harris H. 2007. Randomized, double-blind, placebo-controlled trial of cephalexin for treatment of uncomplicated skin abscesses in a population at risk for community-acquired methicillin-resistant Staphylococcus aureus infection. Antimicrob Agents Chemother 51:4044-4048. http://dx.doi.org/10.1128/AAC.00377-07.
6. Berube BJ, Bubeck Wardenburg J. 2013. Staphylococcus aureus alphatoxin: nearly a century of intrigue. Toxins (Basel) 5:1140-1166. http://dx.doi.org/10.3390/toxins5061140.
7. Spaan AN, Schiepers A, de Haas CJ, van Hooijdonk DD, Badiou C, Contamin H, Vandenesch F, Lina G, Gerard NP, Gerard C, van Kessel KP, Henry T, van Strijp JA. 2015. Differential interaction of the staphylococcal toxins Panton-Valentine leukocidin and gamma-hemolysin CB with human C5a receptors. J Immunol 195:1034-1043. http://dx.doi.org/10.4049/jimmunol.1500604.
8. Loffler B, Hussain M, Grundmeier M, Bruck M, Holzinger D, Varga G, Roth J, Kahl BC, Proctor RA, Peters G. 2010. Staphylococcus aureus Panton-Valentine leukocidin is a very potent cytotoxic factor for human neutrophils. PLoS Pathog 6:e1000715. http://dx.doi.org/10.1371/journal.ppat.1000715.
9. Diep BA, Chan L, Tattevin P, Kajikawa O, Martin TR, Basuino L, Mai TT, Marbach H, Braughton KR, Whitney AR, Gardner DJ, Fan X, Tseng CW, Liu GY, Badiou C, Etienne J, Lina G, Matthay MA, DeLeo FR, Chambers HF. 2010. Polymorphonuclear leukocytes mediate Staphylococcus aureus Panton-Valentine leukocidin-induced lung inflammation and injury. Proc Natl Acad Sci U S A 107:5587-5592. http://dx.doi.org/10.1073/pnas.0912403107.
10. Spaan AN, Henry T, van Rooijen WJ, Perret M, Badiou C, Aerts PC, Kemmink J, de Haas CJ, van Kessel KP, Vandenesch F, Lina G, van Strijp JA. 2013. The staphylococcal toxin Panton-Valentine leukocidin targets human C5a receptors. Cell Host Microbe 13:584-594. http://dx.doi.org/10.1016/j.chom.2013.04.006.
11. Schlievert PM. 2009. Cytolysins, superantigens, and pneumonia due to community-associated methicillin-resistant Staphylococcus aureus. J Infect Dis 200:676-678. http://dx.doi.org/10.1086/605333.
12. Kobayashi SD, Malachowa N, Whitney AR, Braughton KR, Gardner DJ, Long D, Bubeck Wardenburg J, Schneewind O, Otto M, Deleo FR. 2011. Comparative analysis of USA300 virulence determinants in a rabbit model of skin and soft tissue infection. J Infect Dis 204:937-941. http://dx.doi.org/10.1093/infdis/jir441.
13. Li M, Cheung GY, Hu J, Wang D, Joo HS, Deleo FR, Otto M. 2010. Comparative analysis of virulence and toxin expression of global community-associated methicillin-resistant Staphylococcus aureus strains. J Infect Dis 202:1866-1876. http://dx.doi.org/10.1086/657419.
14. Daum RS. 2007. Clinical practice. Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. N Engl J Med 357:380-390.
15. Diep BA, Carleton HA, Chang RF, Sensabaugh GF, Perdreau-Remington F. 2006. Roles of 34 virulence genes in the evolution of hospital- and community-associated strains of methicillin-resistant Staphylococcus aureus. J Infect Dis 193:1495-1503. http://dx.doi.org/10.1086/503777.
16. Bae T, Schneewind O. 2006. Allelic replacement in Staphylococcus aureus with inducible counter-selection. Plasmid 55:58-63. http://dx.doi.org/10.1016/j.plasmid.2005.05.005.
17. Schneider CA, Rasband WS, Eliceiri KW. 2012. NIH Image to ImageJ: 25 years of image analysis. Nat Methods 9:671-675. http://dx.doi.org/10.1038/nmeth.2089.
18. Tkaczyk C, Hamilton MM, Datta V, Yang XP, Hilliard JJ, Stephens GL, Sadowska A, Hua L, O'Day T, Suzich J, Stover CK, Sellman BR. 2013. Staphylococcus aureus alpha toxin suppresses effective innate and adaptive immune responses in a murine dermonecrosis model. PLoS One 8:e75103. http://dx.doi.org/10.1371/journal.pone.0075103.
19. Hua L, Hilliard JJ, Shi Y, Tkaczyk C, Cheng LI, Yu X, Datta V, Ren S, Feng H, Zinsou R, Keller A, O'Day T, Du Q, Cheng L, Damschroder M, Robbie G, Suzich J, Stover CK, Sellman BR. 2014. Assessment of an anti-alpha-toxin monoclonal antibody for prevention and treatment of Staphylococcus aureus-induced pneumonia. Antimicrob Agents Chemother 58:1108-1117. http://dx.doi.org/10.1128/AAC.02190-13.
20. Tkaczyk C, Hua L, Varkey R, Shi Y, Dettinger L, Woods R, Barnes A, MacGill RS, Wilson S, Chowdhury P, Stover CK, Sellman BR. 2012. Identification of anti-alpha toxin monoclonal antibodies that reduce the severity of Staphylococcus aureus dermonecrosis and exhibit a correlation between affinity and potency. Clin Vaccine Immunol 19:377-385. http://dx.doi.org/10.1128/CVI.05589-11.
21. Hilliard JJ, Datta V, Tkaczyk C, Hamilton M, Sadowska A, Jones- Nelson O, O'Day T, Weiss WJ, Szarka S, Nguyen V, Prokai L, Suzich J, Stover CK, Sellman BR. 2015. Anti-alpha-toxin monoclonal antibody and antibiotic combination therapy improves disease outcome and accelerates healing in a Staphylococcus aureus dermonecrosis model. Antimicrob Agents Chemother 59:299-309. http://dx.doi.org/10.1128/AAC.03918-14.
22. Diep BA, Palazzolo-Ballance AM, Tattevin P, Basuino L, Braughton KR, Whitney AR, Chen L, Kreiswirth BN, Otto M, DeLeo FR, Chambers HF. 2008. Contribution of Panton-Valentine leukocidin in community-associated methicillin-resistant Staphylococcus aureus pathogenesis. PLoS One 3:e3198. http://dx.doi.org/10.1371/journal.pone.0003198.
23. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, Ryback MJ, Talan DA, Chambers HF. 2011. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 52:285-292. http://dx.doi.org/10.1093/cid/cir034.
24. Diep BA, Afasizheva A, Le HN, Kajikawa O, Matute-Bello G, Tkaczyk C, Sellman B, Badiou C, Lina G, Chambers HF. 2013. Effects of linezolid on suppressing in vivo production of staphylococcal toxins and improving survival outcomes in a rabbit model of methicillin-resistant Staphylococcus aureus necrotizing pneumonia. J Infect Dis 208:75-82. http://dx.doi.org/10.1093/infdis/jit129.
25. Stevens DL, Ma Y, Salmi DB, McIndoo E, Wallace RJ, Bryant AE. 2007. Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus. J Infect Dis 195:202-211. http://dx.doi.org/10.1086/510396.
26. Sharma-Kuinkel BK, Zhang Y, Yan Q, Ahn SH, Fowler VG, Jr. 2013. Host gene expression profiling and in vivo cytokine studies to characterize the role of linezolid and vancomycin in methicillin-resistant Staphylococcus aureus (MRSA) murine sepsis model. PLoS One 8:e60463. http://dx.doi.org/10.1371/journal.pone.0060463.
27. Dailey CF, Pagano PJ, Buchanan LV, Paquette JA, Haas JV, Gibson JK. 2003. Efficacy of linezolid plus rifampin in an experimental model of methicillin-susceptible Staphylococcus aureus endocarditis. Antimicrob Agents Chemother 47:2655-2658. http://dx.doi.org/10.1128/AAC.47.8.2655-2658.2003.
28. Dryden MS. 2011. Linezolid pharmacokinetics and pharmacodynamics in clinical treatment. J Antimicrob Chemother 66(Suppl 4):iv7-iv15. http://dx.doi.org/10.1093/jac/dkr072.
29. Chambers HF, Deleo FR. 2009. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol 7:629-641. http://dx.doi.org/10.1038/nrmicro2200.
30. Fowler VG, Jr, Proctor RA. 2014. Where does a Staphylococcus aureus vaccine stand? Clin Microbiol Infect 20(Suppl 5):S66-S75. http://dx.doi.org/10.1111/1469-0691.12570.
31. Oznurlu Y, Celik I, Sur E, Telatar T, Ozparlak H. 2009. Comparative skin histology of the White New Zealand and Angora rabbits: histometrical and immunohistochemical evaluations. J Anim Vet Adv 8:1694-1701.
32. Boudry I, Trescos Y, Vallet V, Cruz C, Lallement G. 2008. Methods and models for percutaneous absorption studies of organophosphates. Pathol Biol (Paris) 56:292-299. (In French.) http://dx.doi.org/10.1016/j.patbio.2007.09.024.
33. Wang R, Braughton KR, Kretschmer D, Bach TH, Queck SY, Li M, Kennedy AD, Dorward DW, Klebanoff SJ, Peschel A, DeLeo FR, Otto M. 2007. Identification of novel cytolytic peptides as key virulence determinants for community-associated MRSA. Nat Med 13:1510-1514. http://dx.doi.org/10.1038/nm1656.
34. Kennedy AD, Bubeck Wardenburg J, Gardner DJ, Long D, Whitney AR, Braughton KR, Schneewind O, DeLeo FR. 2010. Targeting of alpha-hemolysin by active or passive immunization decreases severity of USA300 skin infection in a mouse model. J Infect Dis 202:1050-1058. http://dx.doi.org/10.1086/656043.
35. Oganesyan V, Peng L, Damschroder MM, Cheng L, Sadowska A, Tkaczyk C, Sellman BR, Wu H, Dall'Acqua WF. 2014. Mechanisms of neutralization of a human anti-alpha-toxin antibody. J Biol Chem 289: 29874-29880. http://dx.doi.org/10.1074/jbc.M114.601328.
36. Alonzo F, III, Torres VJ. 2014. The bicomponent pore-forming leucocidins of Staphylococcus aureus. Microbiol Mol Biol Rev 78:199-230. http://dx.doi.org/10.1128/MMBR.00055-13.
37. Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL, Hirschmann JV, Kaplan SL, Montoya JG, Wade JC. 2014. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis 59:e10-e52. http://dx.doi.org/10.1093/cid/ciu296.